SCHEMBL4573342

SCHEMBL4573342

Cc1cc(N2CCNCC2)ccc1C(C)(C)C(N)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 5/20 0.55
ACVR1 Q04771 8/20 0.44
HTR7 P34969 3/20 0.44
TGFBR1 P36897 4/20 0.43
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HTR1A P08908 2/20 0.40
HTR3E A5X5Y0 2/20 0.40
HTR3B O95264 2/20 0.40
HTR3A P46098 2/20 0.40
HTR3D Q70Z44 2/20 0.40
HTR3C Q8WXA8 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
HTR6 P50406 2/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4573292 0.85 ADRB1 (0.54) ADRB1ACVR1HTR7TGFBR1USP2
SCHEMBL4573825 0.83 ACVR1 (0.51) ADRB1ACVR1HTR7TGFBR1HTR1A
SCHEMBL14008974 0.81 ADRB1 (0.67) ADRB1HTR7ALDH1A1HTR1AHTR3E
SCHEMBL4541552 0.79 ADRB1 (0.50) ADRB1ACVR1TGFBR1USP2ALDH1A1
SCHEMBL30798753 0.77 ADRB1 (0.61) ADRB1ACVR1HTR7TGFBR1USP2
SCHEMBL1741562 0.77 ADRB1 (0.61) ADRB1ACVR1HTR7TGFBR1USP2
SCHEMBL4573103 0.75 ADRB1 (0.58) ADRB1HTR7ALDH1A1HTR1AHTR3E
SCHEMBL29138207 0.74 ADRB1 (0.61) ADRB1ACVR1HTR7TGFBR1USP2
SCHEMBL1422991 0.74 ADRB1 (0.81) ADRB1HTR7USP2ALDH1A1TSHR
SCHEMBL27107055 0.73 ADRB1 (0.63) ADRB1ACVR1HTR7USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009001127-A1 CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS ASTRAZENECA AB (SE) 2008-12-31 WO disclosed